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bjectives We sought to determine the relationship between red blood cell (RBC) transfusion and
linical outcomes in patients undergoing primary percutaneous coronary intervention (PCI) for acute
yocardial infarction (AMI).
ackground The implications of RBC transfusion in patients undergoing primary PCI for AMI have
ot been evaluated.
ethods Clinical outcomes of patients from the prospective, randomized CADILLAC (Controlled
bciximab and Device Investigation to Lower Late Angioplasty Complications) trial were analyzed by
dministration of in-hospital RBC transfusion not related to coronary artery bypass surgery.
esults Of 2,060 randomized patients, 82 (3.98%) received RBC transfusion during the index hospi-
alization, including 33 (1.60%) with moderate/severe bleeding and 49 (2.38%) without overt major
leeding. Transfusion was independently associated with baseline anemia (odds ratio [95% conﬁ-
ence interval]: 4.44 [2.60 to 7.58], p  0.0001), older age (1.03 [1.01 to 1.06], p  0.002), triple-
essel disease (2.54 [1.47 to 4.38], p  0.0008), and female sex (1.04 [1.02 to 1.06], p  0.0008). Pa-
ients transfused versus not transfused had signiﬁcantly higher rates of 1-year mortality (23.9% vs.
.4%), disabling stroke (2.5% vs. 0.5%), reinfarction (7.0% vs. 2.2%), and composite major adverse
ardiac events (41.0% vs. 16.6%) (all p values  0.01). After multivariable adjustment for potential
onfounders including transfusion propensity, RBC transfusion was independently associated with
ortality at 30 days (hazards ratio: 4.71, p  0.0005) and 1 year (hazards ratio: 3.16, p  0.0005).
onclusions An RBC transfusion after primary PCI in AMI may be harmful, which is consistent with the
ndings from other studies after PCI in the noninfarct setting. Alternatively, RBC transfusion may be a
arker of markedly increased risk. Randomized studies are warranted to determine the optimal thresh-
ld for RBC transfusion in patients with AMI undergoing mechanical reperfusion therapy. (J Am Coll
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625espite the widespread use of blood product transfusions in
atients with chronic anemia and active hemorrhage, there
re limited data to guide transfusion decisions in patients
ith coronary artery disease (CAD). Improved survival in
atients with CAD after red blood cell (RBC) transfusions
as not been prospectively demonstrated. The majority of
vailable data examining outcomes after RBC transfusions
re from retrospective studies, the results of which have
een conflicting. In 3 series of patients with acute myocar-
ial infarction (AMI), the prognostic impact of RBC
ransfusion varied, possibly due to differences in the baseline
See page 633
emoglobin level (1–3). However, in 3 other reports (4–6),
atients with acute coronary syndromes had markedly higher
ates of death, MI, and recurrent ischemia after RBC transfu-
ion. Among 4,131 patients with ST-segment elevation myo-
ardial infarction (STEMI) in the GUSTO (Global Use of
trategies to Open Occluded Coronary Arteries) IIb trial
reated with pharmacological reperfusion, blood transfusion
as associated with more than 2-fold increase in 30-day and
-year mortality and remarkably increased rates of reinfarc-
ion (6). In the same analysis, as well in the study on patients
n the setting of nonemergency percutaneous coronary
ntervention (PCI), blood transfusion was found to be an
ndependent predictor of in-hospital and 1-year mortality
6,7).
The clinical implications of blood transfusion in patients
ndergoing primary PCI for AMI have not been evaluated.
e therefore sought to determine the relationship between
BC transfusions and clinical outcomes from a large,
rospective, multicenter, randomized trial of patients un-
ergoing primary PCI for AMI.
ethods
atient population and protocol. In the CADILLAC
Controlled Abciximab and Device Investigation to Lower
ate Angioplasty Complications) trial, a total of 2,082
atients of any age with AMI within 12-h onset undergoing
rimary PCI in a native coronary artery eligible for stent
mplantation were randomized to 1 of 4 mechanical reper-
usion strategies: percutaneous transluminal coronary bal-
oon angioplasty with or without abciximab (Centocor,
alvern, Pennsylvania) versus stenting with the Multilink
tent (Guidant Corp., Santa Clara, California) with or
ithout abciximab. The design and principal results of the
ADILLAC trial have been reported previously (8). Major
linical inclusion criteria were age 18 years and symptoms
onsistent with MI lasting 30 min but 12 h in duration.
ith regard to hemorrhagic risk, patients were excluded
ho had a history of bleeding diathesis, major surgery
ithin the preceding 6 weeks, gastrointestinal or genitouri- rary bleeding within 6 months, cerebrovascular event within
years or any permanent residual neurological defect, a
istory of leukopenia, thrombocytopenia, hepatic or renal
ysfunction, or recent administration of a thrombolytic
gent. Other exclusion criteria were cardiogenic shock,
llergy or intolerance to study medications (including aspi-
in, unfractionated heparin, abciximab, thienopyridines, or
ontrast media), hepatic or renal dysfunction, and noncar-
iac illness with life expectancy 1 year.
Prior to catheterization, patients received 325 mg of
spirin, ticlopidine 500 mg or clopidogrel 300 mg, a
,000-IU heparin bolus, and intravenous beta-blockade in
he absence of contraindications. Abciximab was adminis-
ered as a bolus of 0.25 mg/kg, followed by a 12-h infusion
t 0.125 g/kg/min (10 g/min maximum). Heparin dos-
ng was guided by nomogram to achieve an activated
lotting time350 s in the absence of abciximab and 200 to
00 s if randomized to abciximab. Heparin infusion after
rimary angioplasty was permit-
ed for patients treated without
bciximab as per operator discre-
ion, but not in patients receiv-
ng abciximab. Following PCI,
edical therapy included aspirin
25 mg daily, beta-blockers and
ngiotensin-converting enzyme
nhibitors if not contraindicated.
atients receiving stents were
reated with oral ticlopidine 250
g twice daily or clopidogrel 75
g daily for 4 weeks. Clinical
ollow-up was performed at 1, 6,
nd 12 months.
nalysis plan, end points, and
eﬁnitions. Clinical outcomes
uring the index hospitalization,
t 30 days and at 1 year were examined according to
dministration of in-hospital RBC transfusion. Further-
ore, to explore the impact of the indication for blood
ransfusions, patients were stratified into 3 groups: 1)
atients administered 1 or more units of RBC transfusions
ue to moderate or severe bleeding; 2) patients administered
BC transfusions in the absence of overt major bleeding;
nd 3) patients that did not receive RBC transfusions.
atients undergoing coronary artery bypass graft (CABG)
urgery during index hospitalization were excluded from the
resent analysis.
The primary composite end point of the CADILLAC
rial included death from any cause, reinfarction, target
essel revascularization as a result of ischemia, or disabling
troke, as previously defined (8). Moderate bleeding was a
linically evident hemorrhage requiring transfusion, and
evere bleeding was defined as clinically evident hemorrhage
Abbreviations
and Acronyms
AMI  acute myocardial
infarction
CABG  coronary artery
bypass graft
CAD  coronary artery
disease
MI  myocardial infarction
PCI  percutaneous
coronary intervention
RBC  red blood cell
STEMI  ST-segment
elevation myocardial
infarction
TIMI  Thrombolysis In
Myocardial Infarctionesulting in hemodynamic compromise or hemorrhagic
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626troke. Anemia was defined using the World Health Orga-
ization criteria as a hematocrit value at initial presentation
f 39% for men and 36% for women (9). Chronic renal
nsufficiency was defined as an estimated glomerular filtra-
ion rate of 60 ml/min/1.73 m2 (Levey modified modifi-
ation of diet in renal disease [MDRD] formula) (10). The
tudy was approved by the institutional review board at each
enter. Written informed consent was obtained from each
atient before enrollment.
tatistical analysis. Categorical variables were compared
sing the Fisher exact test. Continuous variables are pre-
ented as medians with interquartile ranges and were com-
ared using the nonparametric Kruskal-Wallis test. Clinical
utcomes data were estimated by the Kaplan-Meier method
nd compared by log-rank test.
Multivariable analysis of predictors of mortality was
erformed using time-dependent Cox proportional hazards
egression with stepwise selection using alpha entry and exit
riteria of 0.10 and 0.15, respectively. An RBC trans-
usion was treated as a time-dependent covariate and the
dditional candidate variables entered in the model included
ge, sex, diabetes mellitus, hypertension, hypercholesterol-
mia, current smoking, history of prior MI or CABG
urgery, Killip class 2, baseline anemia, creatinine clear-
nce, left anterior descending artery as an infarct vessel,
riple vessel disease, treatment with abciximab or stent,
aseline reference vessel diameter, minimal luminal diame-
er, final Thrombolysis In Myocardial Infarction (TIMI)
ow grade, time from the symptom onset to the first balloon
nflation, admission medications, and moderate/severe
leeding as a time-dependent covariate. To account for the
onfounding effect between transfusions and clinical out-
omes, a propensity score for RBC transfusions was con-
tructed and included in the multivariable model. The
ropensity model was developed using a multivariable lo-
istic model; its discrimination was assessed by the goodness
f fit with the Hosmer-Lemeshow statistic, and its predic-
ive performance was assessed with the C statistic.
esults
ncidence of blood transfusion after primary angioplasty.
uring the index hospitalization, of 2,060 randomized
atients not treated with CABG surgery, 82 patients
3.98%) received RBC transfusions, including 33 patients
1.60%) in whom a transfusion was administered in the
etting of moderate or severe bleeding, and 49 patients
2.38%) who were transfused in the absence of moderate or
evere bleeding. The RBC transfusions were administered
o 75 of 1,681 patients (4.5%) enrolled in the U.S. as
ompared with 7 of 379 patients (1.8%) enrolled in other
ountries (p  0.015). One RBC unit was transfused in
.5% of patients, 2 U in 54.9%, and3 U in 36.6% (median
interquartile range]  2 [2 to 4]). rorrelates of blood transfusion. As seen in Table 1, patients
ho received RBC transfusions were older, more frequently
emale, had a higher prevalence of prior gastrointestinal
leeding, chronic renal insufficiency, multivessel disease,
nd lower body mass index. Baseline values of hemoglobin
nd hematocrit were lower, and as such, anemia at base-
ine was more frequent in patients receiving RBC transfu-
ions. Patients who received RBC transfusions more fre-
uently were treated with calcium-channel blockers and
ngiotensin-converting enzyme inhibitors before admission,
nd less frequently with beta-blockers. Time from AMI
nset to the first balloon inflation was longer in patients
ho received RBC transfusions. As shown in Table 2,
onger procedure duration, post-procedure TIMI flow grade
/2, smaller post-procedure reference vessel diameter, and
ower rates of procedural success were also associated with
ubsequent RBC transfusion. Administration of abciximab
er randomization did not differ significantly between the 2
roups; however, more patients in the transfusion group
eceived abciximab for bail-out indication.
ematological indices and blood product use. Patients who
eceived RBC transfusions associated with moderate or
evere bleeding versus those without overt major bleeding
ersus those not transfused had significantly lower nadir
ematocrit values (28.5% [26.3% to 30.6%] vs. 30.4%
26.9% to 33.0%] vs. 37.0% [33.9% to 40.0%], respectively,
 0.0001) and significantly lower nadir hemoglobin
alues during the index hospitalization (9.6 [9.0 to 10.5]
/dl vs. 10.2 [8.6 to 11.4] g/dl vs. 12.6 [11.5 to 13.7] g/dl,
espectively, p  0.0001). A histogram of nadir hematocrit
alues in patients administered RBC transfusion is shown in
igure 1. In more than one-half of the patients, the nadir
ematocrit of transfused patients was 30% (44 of 82
atients; 53.7%). At hospital discharge, patients who re-
eived RBC transfusions associated with moderate or severe
leeding versus those without moderate or severe bleeding
ersus those not transfused had a significantly lower hemat-
crit (32.8% [29.7% to 33.9%] vs. 33.0% [29.6% to 36.1%]
s. 37.7% [34.1% to 40.7%], respectively, p  0.0001) and
emoglobin (11.0 [9.7 to 11.7] g/dl vs. 10.9 [10.1 to 12.3]
/dl vs. 12.7 [11.6 to 13.8] g/dl, respectively, p  0.0001).
Thrombocytopenia during the index hospitalization (na-
ir platelet count 100  109/l) was also more common in
atients receiving versus those not receiving RBC transfu-
ions [7.3% vs. 3.2%, p  0.05], as was transfusion of
latelets (6.1% vs. 0.2%, p  0.0001) and fresh frozen
lasma (6.1% vs. 0.1%, p  0.0001).
linical outcomes. Infarct size, as estimated by the peak
ost-procedural creatine phosphokinase level, tended to be
arger in patients with versus those without RBC transfu-
ion (2,022 [753 to 2,838] U/l vs. 1,386 [599 to 2,582] U/l,
espectively; p  0.06).
Clinical outcomes are presented in Figure 2. Patients
eceiving versus those not receiving RBC transfusions dur-
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627ng the index hospitalization had markedly higher rates of
0-day and 1-year mortality, disabling stroke, reinfarction,
nd composite major adverse cardiac events. Patients who
eceived blood transfusions without associated moderate or
evere bleeding tended to have higher rates of 30-day and
-year death, target vessel revascularization, and composite
ajor adverse cardiac events than did patients who received
ransfusions in the setting of clinically evident hemorrhage
Table 1. Baseline Clinical Characteristics and Angiographic Features Acco
Red Bloo
Clinical characteristics
Male sex
Age, yrs 6
Diabetes mellitus
Hypertension
Hyperlipidemia
Current smoking
Prior myocardial infarction
Prior percutaneous coronary intervention
Prior coronary bypass surgery
Prior stroke or transient ischemic attack
History of peripheral vascular disease
History of gastrointestinal bleeding
History of genitourinary bleeding
Killip class 2
Body mass index, kg/m2 25
Baseline anemia
Baseline hemoglobin, g/dl 13
Baseline hematocrit, % 38
Baseline platelet count, 103 cells/mm3 24
Baseline creatinine clearance, ml/min
Chronic renal insufﬁciency, %
ST-segment elevation or left bundle branch block
Symptom to balloon inﬂation, h 4
Angiographic features
Single-vessel disease
Double-vessel disease
Triple-vessel disease
Left ventricle ejection fraction, %
Infarct-related artery
Left anterior descending artery
Left circumﬂex artery
Right coronary artery
Medications on admission
Aspirin
Thienopyridine
ACE inhibitor or ARB
Beta-blocker
Calcium-channel blocker
Statin
Data are presented as percentages and as median [interquartile range].
ACE angiotensin-converting enzyme; ARB angiotensin receptor blocker.Table 3). Lultivariable analysis. The propensity model for RBC
ransfusion during the index hospitalization included base-
ine anemia (odds ratio [95% confidence interval]: 4.44
2.60 to 7.58], p  0.0001), older age (1.03 [1.01 to 1.06],
 0.002), triple-vessel disease (2.54 [1.47 to 4.38], p 
.0008), and female sex (1.04 [1.02 to 1.06], p  0.0008),
ut not randomization to abciximab. The C statistic of 0.76
rom the model and the p value of 0.54 from the Hosmer-
to Blood Transfusion Administration
Transfusion
2)
No Transfusion
(n  1,978) p Value
% 74.1% 0.0001
–74] 59 [50–68] 0.0001
% 24.3% 0.13
% 47.7% 0.09
% 37.6% 0.35
% 43.7% 0.09
% 14.0% 0.10
% 11.4% 0.15
% 1.9% 0.21
% 2.9% 0.30
% 2.6% 0.07
% 0.9% 0.002
% 0.2% 1.00
10.4% 0.07
–28.7] 27.3 [28.8–30.5] 0.005
% 10.8% 0.0001
–14.5] 14.7 [13.6–15.6] 0.0001
–43.0] 43.1 [40.1–45.9] 0.0001
–307] 230 [193–272] 0.04
92] 89 [67–113] 0.0001
% 17.3% 0.0001
% 88.0% 0.72
–7.8] 4.0 [2.9–6.1] 0.05
% 52.0% 0.17
% 33.3% 0.34
% 14.7% 0.002
55] 50 [40–56] 0.07
% 36.7% 0.91
% 17.2% 0.55
% 45.8% 0.65
% 27.4% 0.45
% 2.6% 1.0
% 9.0% 0.01
% 15.1% 0.06
% 14.8% 0.0001
% 11.6% 0.15rding
d Cell
(n  8
47.6
7.5 [58
23.2
57.3
42.7
34.1
7.3
6.1
3.7
4.9
6.1
6.1
0.0
17.1
.9 [25.8
36.6
.1 [11.8
.7 [34.4
8 [193
64 [46–
38.0
86.8
.4 [3.4
43.9
28.0
28.0
45 [35–
37.8
19.5
42.7
23.2
2.4
18.3
7.3
34.1
17.1emeshow goodness of fit test indicated good model fit.
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628fter multivariable adjustment for potential confounders
ransfusion propensity, RBC transfusion was identified as
n independent predictor of mortality at 30 days and at 1
ear (Table 4).
iscussion
he principal findings of this analysis, the first such inves-
igation examining the relationship between blood transfu-
ion and outcomes in patients undergoing primary PCI for
MI, are the following: 1) RBC transfusion was adminis-
ered to 3.9% of patients, despite the absence of clinically
vert moderate or severe bleeding in more than one-half of
hese cases; 2) baseline anemia represented the strongest
ndependent predictor of RBC transfusion; 3) patients
eceiving RBC transfusion had worse clinical and angio-
raphic features at baseline, longer times from symptom
nset to balloon inflation and PCI duration, worse proce-
ural outcomes, and larger infarct sizes; 4) after adjustment
or potential confounders including baseline anemia and
Table 2. Procedural Results According to Blood Transfusion Administration
Red Blood Cell Transf
(n  82)
TIMI ﬂow
Baseline
Grade 0 or 1 70.4%
Grade 2 7.4%
Grade 3 22.2%
Final
Grade 0 or 1 6.3%
Grade 2 7.5%
Grade 3 86.3%
Reference diameter, mm
Baseline 2.8 [2.5–3.3]
Final 2.9 [2.5–3.2]
Minimal luminal diameter, mm
Baseline 0 [0–0.8]
Final 2.6 [2.5–2.9]
Diameter stenosis, %
Baseline 100 [71–100]
Final 10 [0–19]
Stent implanted
Per randomization 48.8%
As bail-out for complications 7.3%
Abciximab administered
Per randomization 57.6%
As bail-out for complications 9.8%
Volume of contrast media, ml 300 [240–360]
Procedural success 76.9%
Procedure duration, h 1.20 [0.90–1.80]
Data are presented as percentages and as median [interquartile range].
TIMI Thrombolysis In Myocardial Infarction.ransfusion propensity, RBC transfusion (but not anemia) Remained a powerful independent predictor of 30-day and
-year mortality; and 5) the prognosis following RBC
ransfusions tended to be worse among those patients
ithout an associated moderate or severe hemorrhagic event
han in those who were transfused due to clinically evident
ajor bleeding.
hreshold for blood transfusion. The observed 3.9% rate of
BC transfusions not related to CABG surgery after
rimary PCI in patients with AMI enrolled in the CADIL-
AC trial is similar to that previously reported from the
ooperative Cardiovascular Project in patients with AMI
reated either medically or with PCI (4.7%) (1). Notably,
owever, in the present study, the rates of RBC transfusion
ere 2.5-fold higher at U.S. sites than at non-U.S. sites
4.5% vs. 1.8%). This is consistent with pooled analysis from
international randomized trials of 23,096 patients with
on-STEMI in which non-U.S. compared with U.S. pa-
ients had significantly lower adjusted hazards for blood
ransfusion (11). According to the CRUSADE (Can Rapid
No Transfusion
(n  1,978) p Value
67.8% 0.71
10.2% 0.57
22.0% 1.0
1.1% 0.003
2.8% 0.03
96.1% 0.0004
3.0 [2.6–3.3] 0.06
3.0 [2.6–3.4] 0.048
0 [0–0.7] 0.64
2.7 [2.4–3.0] 0.74
100 [75–100] 1.0
11 [4–18] 0.52
49.8% 0.91
8.1% 1.00
50.5% 0.26
2.6% 0.002
295 [211–375] 0.79
92.8% 0.0001
1.02 [0.78–1.35] 0.0005usionisk Stratification of Unstable Angina Patients Suppress
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629dverse Outcomes With Early Implementation of the
merican College of Cardiology/American Heart Associa-
ion Guidelines) National Quality Improvement Initiative
egistry, despite remarkable variability in rates of blood
ransfusion among the U.S. sites, nadir hematocrit of
ransfused patients was constant (3). No data exist whether
here is a difference in transfusion threshold between the
.S. and the non-U.S. sites. Also of note, in the CADIL-
AC trial, more than one-half of RBC transfusions were
dministered in the absence of moderate or severe bleeding
presumably in the setting of baseline anemia secondary to
omorbidities and/or mild bleeding, with or without clinical
eterioration). The nadir hematocrit values that triggered
lood transfusion in the present analysis varied greatly, with
ore than one-half of the patients receiving a blood
ransfusion with a nadir hematocrit value 30%. These
bservations reflect the lack of a uniform standard to guide
he appropriateness of blood product usage (12). Although
ost would agree that blood transfusion is indicated in the
atient with CAD and active bleeding with either hemo-
ynamic deterioration due to hypovolemia or ischemia from
iminished oxygen delivery, whether blood transfusions are
eneficial or harmful in other settings is controversial.
mpact of blood transfusion on subsequent mortality and
dverse cardiovascular events. Previous studies examining
he utility of blood product transfusions in patients with
AD have reported conflicting results. In a retrospective
tudy in 78,974 Medicare beneficiaries with AMI, RBC
ransfusion was associated with lower 30-day mortality
mong patients whose admission hematocrit values were
Figure 1. Histogram of In-Hospital Nadir Hematocrit Values in Patients
Receiving an RBC Transfusion
The mean  standard deviation nadir hematocrit in patients who received
transfusion was 29.9  4.65%. In more than one-half of transfused patients
(53.7%), nadir hematocrit was 30%.30.0%, but with increased 30-day mortality in those with an admission hematocrit of 36.1% (1). In a study of 4,470
ritically ill patients, transfusion in a subgroup of anemic
atients with cardiac disease was associated with improved
urvival (13). However, in the multicenter randomized
ransfusion Requirement in Critical Care (TRICC) trial,
0-day mortality did not differ significantly in a subgroup of
ritically ill normovolemic patients with known cardiovas-
ular disease assigned to a restrictive transfusion strategy
transfusion only for hemoglobin7 g/dl, with hemoglobin
aintained between 7 and 9 g/dl) versus a liberal transfu-
ion strategy (transfusion for hemoglobin 10 g/dl, with
emoglobin maintenance of 10 to 12 g/dl) (14). Two
etrospective studies (4,5) also failed to show a survival
enefit in patients with known CAD treated with RBC
ransfusion. Other studies have suggested RBC transfusions
ay be harmful. In a pooled analysis of 3 large international
rials comprising 24,112 patients with acute coronary syn-
romes, RBC transfusion was an independent predictor of
0-day mortality after adjustment for baseline characteris-
ics, bleeding and transfusion propensity, and nadir hemat-
crit (3). Other studies have also reported higher early and
ate mortality and MI rates after blood transfusion in
atients with acute coronary syndromes and in those under-
oing PCI (5–7).
The impact of blood transfusion in patients treated with
rimary PCI in AMI has not been previously examined. In
he propensity-matched analysis of 316 patients with
TEMI treated with thrombolytic therapy in the GUSTO
Ib trial, transfusion as a time-dependent variable was a
trong and independent predictor of all-cause mortality (6).
n a pooled analysis from 16 TIMI trials treated primarily
ith pharmacologic reperfusion therapies, the impact of
BC transfusion appeared to be different for patients with
TEMI versus patients with non-STEMI (2). Among
5,419 STEMI patients, RBC transfusion was associated
ith a decreased risk of cardiovascular death when the
aseline hemoglobin was 12 g/dl (adjusted odds ratio:
.42), but not when the hemoglobin was12 g/dl (adjusted
dds ratio: 1.42). Among 14,503 patients with non-
TEMI, RBC transfusion correlated with an increased risk
f the composite end point of death, MI, and recurrent
schemia (adjusted odds ratio: 1.54), regardless of the
aseline hemoglobin (2). Finally, in the analysis from the
RUSADE registry, transfusion was associated with lower
n-hospital mortality in patients with nadir hematocrit
24% and higher in-hospital mortality in patients with
adir hematocrit 30%, whereas there was no effect of
ransfusion on in-hospital mortality in the middle group (3).
airly small sample size in this study does not allow
nalyzing in detail the impact of transfusion on outcomes of
atients with different values of nadir hematocrit transfused
n the setting of moderate to severe bleeding or in its
bsence.
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630In the CADILLAC trial, RBC transfusion after primary
CI in AMI was associated with significantly greater rates
f short-term and long-term mortality, disabling stroke,
einfarction, and composite adverse ischemic events. An
BC transfusion was a powerful independent predictor of
ortality at both 30 days and 1 year after multivariable
djustment for potential confounders, suggesting a possible
Figure 2. Kaplan-Meier Estimates of Adverse Events at 1 Year
Cumulative adverse event rates during 1 year of follow-up in patients undergo
stratiﬁed by red blood cell transfusion. (A) Death; (B) reinfarction; (C) target ve
diovascular events (MACE).rimary deleterious effect of blood transfusion. This likeli- tood is made more credible by the observation that adverse
vents occurred more frequently when RBC transfusions
ere administered in the absence of clinically evident
oderate or severe hemorrhagic events. We earlier reported
hat in the CADILLAC trial by multivariable analysis
accounting for blood product transfusion but not for
ropensity score for transfusions), baseline anemia and not
rimary percutaneous coronary intervention for acute myocardial infarction
evascularization; (D) disabling stroke; and (E) composite major adverse car-ing p
ssel rransfusion was an independent predictor of in-hospital and
1
a
t
l
t
t
f
f
c
o
t
b
s
i
t
(
c
d
o
a
r
c
b
w
W
A
p
S
s
r
C
d
r
p
c
d
m
m
d
c
b
t
a
o
t
i
d
s
C
T
f
s
h
g
a
b
t
a
o
e
p
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 7 , 2 0 0 9 Nikolsky et al.
J U L Y 2 0 0 9 : 6 2 4 – 3 2 Transfusion After Primary Angioplasty
631-year mortality after primary PCI (15). In the present
nalysis, after accounting for the transfusion propensity in
he multivariable model, baseline anemia and female sex no
onger predicted early or late mortality. This is likely due to
he powerful relationships among baseline anemia, sex, and
ransfusion. Not surprisingly, in this study both anemia and
emale sex were strongest independent predictors of trans-
usion. Still, the data of the present analysis do not allow
larifying what is the precise mechanism of worse outcomes
f patients treated with blood transfusion. Future prospec-
ive studies should provide the answer whether anemia,
lood product transfusion or both contribute to reduced
urvival in this patient cohort.
The mechanisms through which RBC transfusion might
ncrease cardiovascular risk are undetermined. An RBC
ransfusion may increase the level of systemic inflammation
16). Transfusion of aged RBCs may be high in lactate
ontent and have reduced oxygen carrying capacity due to
epletion of 2,3-diphosphoglycerate, thereby shifting the
xygen dissociation curve to the left (17). Nitric oxide levels
re also known to be significantly depleted in stored eryth-
ocytes, which may impair vasodilation and result in RBC
apillary sludging (18,19). Functional capillary density,
lood flow, and oxygen distribution in microvascular net-
orks are also reduced after stored RBC transfusions (20).
ithdrawal of medications known to prolong survival after
MI poses additional risk in patients with anemia (15) and
robably after transfusion.
tudy limitations. This analysis was necessarily post hoc and
hould therefore be considered hypothesis generating. The
elatively young median age (59 years) of the patients in the
Table 3. Clinical Outcomes at 30 Days and 1 Year in Patients Receiving
Red Blood Cell Transfusions According to Whether Overt Moderate or
Severe Bleeding Was Present
Transfusion in the
Setting of Major
Bleeding
(n  33)
Transfusion
Without Major
Bleeding
(n  49) p Value
Mortality
30 days 6.1% 18.4% 0.11
1 yr 19.0% 29.3% 0.26
Disabling stroke
30 days 3.1% 2.3% 0.83
1 yr 3.0% 2.3% 0.83
Reinfarction
30 days 0.0% 4.4% 0.23
1 yr 7.9% 7.2% 0.90
Target vessel revascularization
30 days 0.0% 8.9% 0.05
1 yr 7.9% 17.3% 0.19
Composite adverse events
30 days 9.1% 30.6% 0.02
1 yr 28.6% 45.0% 0.09ADILLAC trial as well as fairly preserved baseline me-ian left ventricle ejection fraction (60%) may not be
epresentative of the general population. By trial design,
atients with cardiogenic shock and patients with complex
oronary anatomy (e.g., left main disease or bifurcation
isease) were excluded from randomization (8). Although
ultivariable statistical modeling with propensity adjust-
ent was used to correct for baseline and procedural
ifferences, all unmeasured confounders may not have been
ontrolled for, and data regarding the exact triggers for
lood transfusion are unavailable. Blood transfusion may
hus also be a marker of markedly increased risk. The
bsolute number of patients transfused with and without
vert bleeding is insufficient to definitively conclude that
ransfusion in the absence of bleeding is harmful, especially
n severely anemic patients. Nor should these data be used to
erive recommendations for the most appropriate transfu-
ion threshold.
onclusions and Clinical Implications
he limitations notwithstanding, the present study, derived
rom a large, multicenter clinical trial, suggests that at least
ome RBC transfusions after primary PCI in AMI may be
armful. In this regard, the current study contributes to a
rowing body of published data suggesting that the liberal
dministration of blood products in patients with AMI may
e deleterious. Additional studies are required to confirm
hese results and explore the underlying mechanisms of
dverse impact of transfusion on clinical outcomes. More-
ver, randomized studies are warranted and required to
stablish the optimal threshold for RBC transfusion in
atients undergoing PCI in the AMI and noninfarct set-
ings and to evaluate the safety of blood transfusion versus
Table 4. Multivariable Predictors of Mortality at 30 Days and 1 Year
Hazard Ratio
(95% Confidence Interval) p Value
30-day mortality
Renal insufﬁciency 5.96 (2.73–13.03) 0.0001
Left anterior descending
artery infarct vessel
5.06 (2.32–11.02) 0.0001
Blood transfusion 4.71 (1.97–11.26) 0.0005
Propensity to transfusion 1.60 (1.04–2.45) 0.032
Hypertension 2.91 (1.24–6.81) 0.014
1-year mortality
Blood transfusion 3.16 (1.66–6.03) 0.0005
Left anterior descending
artery infarct vessel
2.41 (1.47–3.96) 0.0005
Renal insufﬁciency 2.60 (1.42–4.74) 0.002
Killip class 2 or 3 2.28 (1.30–4.02) 0.004
Baseline minimal luminal
diameter
0.44 (0.24–0.81) 0.0008
Age 1.03 (1.01–1.06) 0.015Propensity to transfusion 1.43 (1.03–1.99) 0.033
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632lternative treatments (e.g., erythropoietin or artificial oxy-
en carriers).
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